As FLT3‐ITD and miR‐125b are two common oncogenes in AML, combined treatments with ASOs targeting FLT3‐ITD and miR‐125b are expected to have synergistic therapeutic effects that are more potent than each ASO alone. Here, FLT3 is linked to acute myeloid leukemia.